Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy

Bryostatin 1 is a unique therapeutic lead, however its scarce natural sources have hampered its use in treatment of human disease. Here, the authors use a scalable synthesis of bryostatin 1 to make close-in analogs which potently induce increased cell surface expression holding potential for immunot...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Clayton Hardman, Stephen Ho, Akira Shimizu, Quang Luu-Nguyen, Jack L. Sloane, Mohamed S. A. Soliman, Matthew D. Marsden, Jerome A. Zack, Paul A. Wender
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Q
Acceso en línea:https://doaj.org/article/ebe37911de374c93a36c1ee604f378a0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Bryostatin 1 is a unique therapeutic lead, however its scarce natural sources have hampered its use in treatment of human disease. Here, the authors use a scalable synthesis of bryostatin 1 to make close-in analogs which potently induce increased cell surface expression holding potential for immunotherapy.